Aurobindo Pharma Subsidiary Faces Five Observations from U.S. FDA

Aurobindo Pharma subsidiary APL Healthcare's unit in Andhra Pradesh received five observations from the US FDA. The observations are procedural in nature and the company will respond within the stipulated timelines. The company is committed to maintaining the highest quality manufacturing standards at all its facilities worldwide. This comes after the FDA issued three observations to another subsidiary's API manufacturing facility in Hyderabad.